{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:23:12Z","timestamp":1783405392577,"version":"3.54.6"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR066109"],"award-info":[{"award-number":["K24 AR066109"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10067-024-07206-w","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T02:02:08Z","timestamp":1729821728000},"page":"3839-3847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increased risk of adverse events among patients with vs. without systemic autoimmune rheumatic disease prescribed sodium-glucose cotransporter 2 inhibitors: a retrospective cohort study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1701-6258","authenticated-orcid":false,"given":"Emily G.","family":"Oakes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Ellrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen H.","family":"Costenbader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"issue":"9","key":"7206_CR1","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/db12-0052","volume":"61","author":"J Liu","year":"2012","unstructured":"Liu J, Lee T, Defronzo RA (2012) Why do SGLT2 inhibitors inhibit only 30\u201350% of renal glucose reabsorption in humans? Diabetes 61(9):2199\u20132204","journal-title":"Diabetes"},{"issue":"10","key":"7206_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation 134(10):752\u2013772","journal-title":"Circulation"},{"issue":"15","key":"7206_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"issue":"1","key":"7206_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.kint.2021.09.005","volume":"101","author":"HJL Heerspink","year":"2022","unstructured":"Heerspink HJL, Cherney D, Postmus D, Stef\u00e1nsson BV, Chertow GM, Dwyer JP et al (2022) A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int 101(1):174\u2013184","journal-title":"Kidney Int"},{"issue":"11","key":"7206_CR5","first-page":"807","volume":"9","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, Jongs N, Postmus D, Correa-Rotter R et al (2021) Effects of dapagliflozin in patients with kidney disease, with and without heart failure. JACC: Heart Failure 9(11):807\u201320","journal-title":"JACC: Heart Failure"},{"issue":"13","key":"7206_CR6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-021-01573-3","volume":"81","author":"L Del Vecchio","year":"2021","unstructured":"Del Vecchio L, Beretta A, Jovane C, Peiti S, Genovesi S (2021) A role for SGLT-2 inhibitors in treating non-diabetic chronic kidney disease. Drugs 81(13):1491\u20131511","journal-title":"Drugs"},{"issue":"4","key":"7206_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Von Eynatten M, Mattheus M et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334","journal-title":"N Engl J Med"},{"issue":"5","key":"7206_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZI Cherney","year":"2014","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587\u2013597","journal-title":"Circulation"},{"issue":"7","key":"7206_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657","journal-title":"N Engl J Med"},{"issue":"1","key":"7206_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T et al (2021) A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215\u2013224","journal-title":"Kidney Int"},{"issue":"2","key":"7206_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J et al (2018) Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137(2):119\u2013129","journal-title":"Circulation"},{"key":"7206_CR12","doi-asserted-by":"crossref","unstructured":"Clar C, Gill JA, Court R, Waugh N (2012) Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2(5)","DOI":"10.1136\/bmjopen-2012-001007"},{"key":"7206_CR13","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.2147\/TCRM.S112236","volume":"12","author":"Z Wang","year":"2016","unstructured":"Wang Z, Hu X, Liu X, Wang Y (2016) An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther Clin Risk Manag 12:1113\u20131131","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"7206_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/MED.0000000000000311","volume":"24","author":"DS Hsia","year":"2016","unstructured":"Hsia DS, Grove O, Cefalu WT (2016) An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 24(1):73\u201379","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"7206_CR15","unstructured":"FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes: U.S. Food and Drug Administration (FDA) (2018). Available from:\nhttps:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes.\u00a0"},{"key":"7206_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.maturitas.2021.06.003","volume":"150","author":"M Kang","year":"2021","unstructured":"Kang M, Heo KN, Ah YM, Yang BR, Lee JY (2021) Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a population-based self-controlled case-series study. Maturitas 150:30\u201336","journal-title":"Maturitas"},{"issue":"11","key":"7206_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jdiacomp.2017.07.018","volume":"31","author":"GA Nichols","year":"2017","unstructured":"Nichols GA, Brodovicz KG, Kimes TM, D\u00e9ruaz-Luyet A, Bartels DB (2017) Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complications 31(11):1587\u20131591","journal-title":"J Diabetes Complications"},{"key":"7206_CR18","doi-asserted-by":"crossref","unstructured":"Uitrakul S, Aksonnam K, Srivichai P, Wicheannarat S, Incomenoy S (2022) The incidence and risk factors of urinary tract infection in patients with type 2 diabetes mellitus using SGLT2 inhibitors: a real-world observational study. Medicines (Basel) 9(12)","DOI":"10.3390\/medicines9120059"},{"issue":"3","key":"7206_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","volume":"126","author":"K Usiskin","year":"2014","unstructured":"Usiskin K, Kline I, Fung A, Mayer C, Meininger G (2014) Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med 126(3):16\u201334","journal-title":"Postgrad Med"},{"issue":"7","key":"7206_CR20","first-page":"45","volume":"35","author":"S Pittampalli","year":"2018","unstructured":"Pittampalli S, Upadyayula S, Mekala HM, Lippmann S (2018) Risks vs Benefits for SGLT2 Inhibitor Medications. Fed Pract 35(7):45\u201348","journal-title":"Fed Pract"},{"issue":"10354","key":"7206_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","volume":"400","author":"N Conrad","year":"2022","unstructured":"Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G et al (2022) Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 400(10354):733\u2013743","journal-title":"Lancet"},{"issue":"51","key":"7206_CR22","doi-asserted-by":"publisher","first-page":"e32520","DOI":"10.1097\/MD.0000000000032520","volume":"101","author":"YJ Lin","year":"2022","unstructured":"Lin YJ, Chien CC, Ho CH, Chen HA, Chen CY (2022) Increased risk of type 2 diabetes in patients with systemic lupus erythematosus: a nationwide cohort study in Taiwan. Medicine 101(51):e32520","journal-title":"Medicine"},{"issue":"4","key":"7206_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/acr.23879","volume":"72","author":"C Morgan","year":"2020","unstructured":"Morgan C, Costello RE, Ray DW, Dixon WG (2020) How do glucocorticoids used in rheumatic disease affect body weight? A narrative review of the evidence. Arthritis Care Res 72(4):489\u201397","journal-title":"Arthritis Care Res"},{"issue":"12","key":"7206_CR24","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1136\/ard.2009.125476","volume":"69","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Love TJ, Canning C, Schneeweiss S (2010) Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69(12):2114\u20132117","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7206_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.kint.2016.03.042","volume":"90","author":"PJ Hoover","year":"2016","unstructured":"Hoover PJ, Costenbader KH (2016) Insights into the epidemiology and management of lupus nephritis from the US rheumatologist\u2019s perspective. Kidney Int 90(3):487\u2013492","journal-title":"Kidney Int"},{"issue":"6","key":"7206_CR26","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"2016","unstructured":"Tektonidou MG, Dasgupta A, Ward MM (2016) Risk of end-stage renal disease in patients with lupus nephritis, 1971\u20132015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68(6):1432\u20131441","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"7206_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2042018814547204","volume":"5","author":"MP Hage","year":"2014","unstructured":"Hage MP, Al-Badri MR, Azar ST (2014) A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther Adv Endocrinol Metab 5(4):77\u201385","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"7206_CR28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1399-0012.2009.00962.x","volume":"23","author":"A Asberg","year":"2009","unstructured":"Asberg A, Midtvedt K, Voytovich MH, Line PD, Narverud J, Reisaeter AV et al (2009) Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation. Clin Transplant 23(4):511\u2013518","journal-title":"Clin Transplant"},{"issue":"5","key":"7206_CR29","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/annrheumdis-2021-221474","volume":"81","author":"M S\u00e4emann","year":"2022","unstructured":"S\u00e4emann M, Kronbichler A (2022) Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors. Ann Rheum Dis 81(5):614\u2013617","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7206_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/dom.12670","volume":"18","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ (2016) Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 18(8):783\u2013794","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"7206_CR31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","volume":"28","author":"P Nyirjesy","year":"2012","unstructured":"Nyirjesy P, Zhao Y, Ways K, Usiskin K (2012) Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 28(7):1173\u20131178","journal-title":"Curr Med Res Opin"},{"key":"7206_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11:43","journal-title":"BMC Med"},{"issue":"3","key":"7206_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H (2017) Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 19(3):348\u2013355","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"7206_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/07853890.2011.560181","volume":"44","author":"G Musso","year":"2012","unstructured":"Musso G, Gambino R, Cassader M, Pagano G (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44(4):375\u2013393","journal-title":"Ann Med"},{"issue":"11","key":"7206_CR35","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dme.13508","volume":"34","author":"S Kumar","year":"2017","unstructured":"Kumar S, Costello AJ, Colman PG (2017) Fournier\u2019s gangrene in a man on empagliflozin for treatment of type 2 diabetes. Diabet Med 34(11):1646\u20131648","journal-title":"Diabet Med"},{"issue":"11","key":"7206_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH (2019) Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 170(11):764\u2013769","journal-title":"Ann Intern Med"},{"issue":"12","key":"7206_CR37","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","volume":"65","author":"E Marilly","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P et al (2022) SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 65(12):2000\u20132010","journal-title":"Diabetologia"},{"issue":"9","key":"7206_CR38","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1111\/dom.14075","volume":"22","author":"J Liu","year":"2020","unstructured":"Liu J, Li L, Li S, Wang Y, Qin X, Deng K et al (2020) Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 22(9):1619\u20131627","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"7206_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","volume":"173","author":"A Douros","year":"2020","unstructured":"Douros A, Lix LM, Fralick M, Dell\u2019Aniello S, Shah BR, Ronksley PE et al (2020) Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis\u202f: a multicenter cohort study. Ann Intern Med 173(6):417\u2013425","journal-title":"Ann Intern Med"},{"issue":"12","key":"7206_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jch.12425","volume":"16","author":"MR Weir","year":"2014","unstructured":"Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A et al (2014) Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens 16(12):875\u201382","journal-title":"J Clin Hypertens"},{"issue":"2","key":"7206_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/acr.24766","volume":"75","author":"DJ S\u00e9guin","year":"2023","unstructured":"S\u00e9guin DJ, Peschken CA, Dolovich C, Grymonpre RE, St John PD, Tisseverasinghe A (2023) Polypharmacy and potentially inappropriate medication use in older adults with systemic lupus erythematosus. Arthritis Care Res 75(2):356\u201364","journal-title":"Arthritis Care Res"},{"key":"7206_CR42","doi-asserted-by":"publisher","first-page":"152386","DOI":"10.1016\/j.semarthrit.2024.152386","volume":"65","author":"BA Kimbrough","year":"2024","unstructured":"Kimbrough BA, Crowson CS, Lennon RJ, Davis JM 3rd, Strangfeld A, Myasoedova E (2024) Multiple morbidities are associated with serious infections in patients with rheumatoid arthritis. Semin Arthritis Rheum 65:152386","journal-title":"Semin Arthritis Rheum"},{"key":"7206_CR43","first-page":"576134","volume":"11","author":"F Motta","year":"2020","unstructured":"Motta F, Sica A, Selmi C (2020) Frailty in rheumatic diseases Front Immunol 11:576134","journal-title":"Frailty in rheumatic diseases Front Immunol"},{"issue":"3","key":"7206_CR44","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2337\/dc21-1676","volume":"45","author":"CE Hawley","year":"2022","unstructured":"Hawley CE, Lauffenburger JC, Paik JM, Wexler DJ, Kim SC, Patorno E (2022) Three sides to the story: adherence trajectories during the first year of SGLT2 inhibitor therapy among medicare beneficiaries. Diabetes Care 45(3):604\u2013613","journal-title":"Diabetes Care"},{"key":"7206_CR45","unstructured":"Jorge A, Zhou B, McCormick N, Yokose C, Zhang Y, Choi HK (2023) Sodium-glucose co-transporter-2 inhibitors and the risk of cardiac and renal outcomes in systemic Lupus Erythematosus [abstract]. ACR Convergence ; San Diego, CA: Arthritis Rheumatol"},{"key":"7206_CR46","doi-asserted-by":"crossref","unstructured":"Ma KS, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH (2024) Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: a Population-based target trial emulation. Arthritis Rheumatol","DOI":"10.1002\/art.43037"},{"key":"7206_CR47","doi-asserted-by":"crossref","unstructured":"Wang H, Li T, Sun F, Liu Z, Zhang D, Teng X, et al (2022) Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial. RMD Open 8:(2)\u00a0","DOI":"10.1136\/rmdopen-2022-002686"},{"key":"7206_CR48","doi-asserted-by":"crossref","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E (2019) Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med 171(4):248\u2013256","DOI":"10.7326\/M18-3136"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07206-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07206-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07206-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T12:02:55Z","timestamp":1732190575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07206-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7206"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07206-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Costenbader acknowledges the following disclosures: Amgen (consultant, grant\/research support); AstraZeneca (grant\/research support); Bristol-Myers Squibb (BMS) (consultant); Cabaletta Bio (consultant); Eli Lilly (consultant); Exagen Diagnostics (grant\/research support); Gilead (grant\/research support); GlaxoSmithKline (GSK) (consultant, grant\/research support); and Janssen (consultant, grant\/research support). Dr. Choi has received consultant fees from AstraZeneca, GlaxoSmithKline (GSK), Werfen, MitogenDx, Mallinckrodt Pharmaceuticals, Organon, and Celltrion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The funders had no role in the decision to publish or preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}